Biotech Investors & VC Firms

2107 firms in this list, with a median first check of $500K. 405 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
VE Vertex Ventures HC CBLHYLAC6 people	88🔒	Singapore	SG	Seed–Growth	$500K – $10M	+ Add to CRM
AL Altium Capital JGJTALDW5 people	88🔒	New York	US	Seed–Growth	—	+ Add to CRM
CU Curie Capital HDMVOTHV8 people · Leads rounds	88🔒	Amsterdam	NL	Seed–Series A	—	+ Add to CRM
TH Thundermark Capital GCJKSTWS8 people	88🔒	San Juan	US	Pre-Seed–Series A	—	+ Add to CRM
CW CWRU Technology Ventures DP1 person	88🔒	Cleveland	US	Pre-Seed–Seed	$50K – $250K	+ Add to CRM
23 23andMe AWAADNFR10 people	88🔒	Mountain View	US	—	—	+ Add to CRM
FE Fengate Private Equity LSGTJMJP10 people	88🔒	Toronto	CA	Growth–Late Stage	—	+ Add to CRM
NE Neo Kuma Ventures CBSMCSDP7 people	88🔒	London	GB	Pre-Seed–Series A	$195K – $1.3M	+ Add to CRM
NE Newlin Investment Company LLC WRSNCAWR4 people	88🔒	Pittsburgh	US	Seed–Growth	$100K – $3M	+ Add to CRM
OW Owl Rock Capital CPDOMLMM4 people · Leads rounds	88🔒	New York	US	Growth–Late Stage	$20M – $250M	+ Add to CRM
ON Ono Venture Investment, Inc. SMDNHTKT6 people	88🔒	South San Francisco	US	Seed–Series B	—	+ Add to CRM
SI Sinai Capital Partners JFNSOH3 people · Follows rounds	88🔒	—		Pre-Seed–Seed	—	+ Add to CRM
UN Unfold Ventures JSAJMSJS6 people	88🔒	Wrocław	PL	Pre-Seed–Late Stage	$110K – $1.1M	+ Add to CRM
WA Wallonie Entreprendre BLCFGLMB9 people	88🔒	Liège	BE	Pre-Seed–Late Stage	—	+ Add to CRM
AM Amzak Health JETNDSMC5 people	88🔒	New York	US	Seed–Late Stage	—	+ Add to CRM
TE Tet Ventures NB1 person · Follows rounds	88🔒	Berlin	DE	Pre-Seed–Series A	$50K – $250K	+ Add to CRM
EG EGORA Ventures AG BLDNPANZ7 people	88🔒	Martinsried	DE	Pre-Seed–Series B	$5.4M	+ Add to CRM
VI VIVES Partners AVPDSSYV4 people	88🔒	Wavre	BE	Pre-Seed–Series B	$108K – $7.6M	+ Add to CRM
AG Agate Medical Investments LP	88🔒	Tel-Aviv	IL	Growth–Late Stage	—	+ Add to CRM
CR Crossbeam Venture Partners AHRMSJ3 people · Leads rounds	88🔒	New York	US	Pre-Seed–Late Stage	$1M – $1.5M	+ Add to CRM
ME MEDA Ventures CCECTPJB9 people	88🔒	Arlington	US	Seed–Series A	—	+ Add to CRM
SI SIDBI Venture Capital AKBMCGPK6 people	88🔒	Mumbai	IN	Seed–Late Stage	—	+ Add to CRM
TR TruVenturo GmbH NRDKFSFH6 people	88🔒	Hamburg	DE	Seed–Series A	—	+ Add to CRM
SI Simsan Ventures SCSCRLMB8 people · Leads rounds	88🔒	London	GB	Pre-Seed–Series A	—	+ Add to CRM

Vertex Ventures HC

SingaporeSeed–Growth$500K – $10M

CBLHYLAC6 people

Altium Capital

New YorkSeed–Growth

JGJTALDW5 people

Curie Capital

AmsterdamSeed–Series A

HDMVOTHV8 people

Thundermark Capital

San JuanPre-Seed–Series A

GCJKSTWS8 people

CWRU Technology Ventures

ClevelandPre-Seed–Seed$50K – $250K

DP1 person

23andMe

Mountain View

AWAADNFR10 people

Fengate Private Equity

TorontoGrowth–Late Stage

LSGTJMJP10 people

Neo Kuma Ventures

LondonPre-Seed–Series A$195K – $1.3M

CBSMCSDP7 people

Newlin Investment Company LLC

PittsburghSeed–Growth$100K – $3M

WRSNCAWR4 people

Owl Rock Capital

New YorkGrowth–Late Stage$20M – $250M

CPDOMLMM4 people

Ono Venture Investment, Inc.

South San FranciscoSeed–Series B

SMDNHTKT6 people

Sinai Capital Partners

Pre-Seed–Seed

JFNSOH3 people

Unfold Ventures

WrocławPre-Seed–Late Stage$110K – $1.1M

JSAJMSJS6 people

Wallonie Entreprendre

LiègePre-Seed–Late Stage

BLCFGLMB9 people

Amzak Health

New YorkSeed–Late Stage

JETNDSMC5 people

Tet Ventures

BerlinPre-Seed–Series A$50K – $250K

NB1 person

EGORA Ventures AG

MartinsriedPre-Seed–Series B$5.4M

BLDNPANZ7 people

VIVES Partners

WavrePre-Seed–Series B$108K – $7.6M

AVPDSSYV4 people

Agate Medical Investments LP

Tel-AvivGrowth–Late Stage

Crossbeam Venture Partners

New YorkPre-Seed–Late Stage$1M – $1.5M

AHRMSJ3 people

MEDA Ventures

ArlingtonSeed–Series A

CCECTPJB9 people

SIDBI Venture Capital

MumbaiSeed–Late Stage

AKBMCGPK6 people

TruVenturo GmbH

HamburgSeed–Series A

NRDKFSFH6 people

Simsan Ventures

LondonPre-Seed–Series A

SCSCRLMB8 people

Data sourced from public filings and firms' own websites — see our methodology.